NCT01966055

Brief Summary

A study of the safety and pharmacokinetics of solithromycin capsules in adolescents

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Dec 2013

Geographic Reach
1 country

11 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 15, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 21, 2013

Completed
1 month until next milestone

Study Start

First participant enrolled

December 1, 2013

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2014

Completed
Last Updated

February 23, 2017

Status Verified

February 1, 2017

Enrollment Period

8 months

First QC Date

October 15, 2013

Last Update Submit

February 20, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Area under the plasma concentration versus time curve (AUC) of solithromycin in adolescents

    5 days

Study Arms (1)

Solithromycin

EXPERIMENTAL
Drug: Solithromycin

Interventions

Solithromycin

Eligibility Criteria

Age12 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • to 17 yo male or female with suspected or confirmed bacterial infection

You may not qualify if:

  • Bacterial meningitis
  • Clinical significant concomitant medical condition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (11)

Unknown Facility

Little Rock, Arkansas, 72202, United States

Location

Unknown Facility

San Diego, California, 92123, United States

Location

Unknown Facility

Chicago, Illinois, 60611, United States

Location

Unknown Facility

Louisville, Kentucky, 40202, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48109, United States

Location

Unknown Facility

Hackensack, New Jersey, 07601, United States

Location

Unknown Facility

New York, New York, 10032, United States

Location

Unknown Facility

Portland, Oregon, 97239, United States

Location

Unknown Facility

Hershey, Pennsylvania, 17033, United States

Location

Unknown Facility

Galveston, Texas, 77555-0701, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Related Publications (3)

  • Beechinor RJ, Cohen-Wolkowiez M, Jasion T, Hornik CP, Lang JE, Hernandez R, Gonzalez D. A Dried Blood Spot Analysis for Solithromycin in Adolescents, Children, and Infants: A Short Communication. Ther Drug Monit. 2019 Dec;41(6):761-765. doi: 10.1097/FTD.0000000000000670.

  • Gonzalez D, James LP, Al-Uzri A, Bosheva M, Adler-Shohet FC, Mendley SR, Bradley JS, Espinosa C, Tsonkova E, Moffett K, Marquez L, Simonsen KA, Stoilov S, Boakye-Agyeman F, Jasion T, Hornik CP, Hernandez R, Benjamin DK Jr, Cohen-Wolkowiez M. Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00692-18. doi: 10.1128/AAC.00692-18. Print 2018 Aug.

  • Gonzalez D, Palazzi DL, Bhattacharya-Mithal L, Al-Uzri A, James LP, Bradley J, Neu N, Jasion T, Hornik CP, Smith PB, Benjamin DK Jr, Keedy K, Fernandes P, Cohen-Wolkowiez M. Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2572-6. doi: 10.1128/AAC.02561-15. Print 2016 Apr.

MeSH Terms

Conditions

Bacterial Infections

Interventions

solithromycin

Condition Hierarchy (Ancestors)

Bacterial Infections and MycosesInfections

Study Officials

  • Michael Cohen-Wolkowiez, MD

    Duke Clinical Research Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 15, 2013

First Posted

October 21, 2013

Study Start

December 1, 2013

Primary Completion

August 1, 2014

Study Completion

September 1, 2014

Last Updated

February 23, 2017

Record last verified: 2017-02

Locations